

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

Brilliant Violet 650(TM) anti-human CD20

RRID:AB_11218609

Type: Antibody

Proper Citation

BioLegend Cat# 302335, RRID:AB_11218609

Antibody Information

URL: http://antibodyregistry.org/AB_11218609

Proper Citation: BioLegend Cat# 302335, RRID:AB_11218609

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-human CD20

Description: This monoclonal targets CD20

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone 2H7

Antibody ID: AB_11218609

Vendor: BioLegend

Catalog Number: 302335

Alternative Catalog Numbers: 302336

Record Creation Time: 20250819T223810+0000

Record Last Update: 20250820T024921+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-human CD20.

No alerts have been found for Brilliant Violet 650(TM) anti-human CD20.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Acciani M, et al. (2026) Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins. Cell host & microbe, 34(6), 1067.

Olmedillas E, et al. (2025) Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation. Cell reports, 44(8), 116052.

Hastie KM, et al. (2023) Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6??months before Omicron emergence. Cell reports, 42(5), 112421.

Weskamm LM, et al. (2022) Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell reports. Medicine, 3(7), 100685.

Weskamm LM, et al. (2022) Flow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens. STAR protocols, 3(4), 101902.

Zabaleta N, et al. (2021) An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell host & microbe, 29(9), 1437.

Buggert M, et al. (2020) The Identity of Human Tissue-Emigrant CD8+ T Cells. Cell, 183(7), 1946.